Particularly, 68Ga-labeled somatostatin receptor PET imaging is extensively used for neuroendocrine tumor imaging while the 68Ga-labeled prostate-specific membrane antigen (PSMA) has been shown to provide valuable information for the clinical management of prostate cancer patients. This evidence concerns the gene FOLH1 and prostate carcinoma.